Vancouver, British Columbia--(Newsfile Corp. - May 2, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the 'Company' or 'PreveCeutical') announces that the Company has missed the filing deadline of April 29, 2024 to file the Company's audited annual financial statements and accompanying management's discussion and analysis, with related CEO and CFO certificates, for the financial year ended December 31, 2023 (collectively, the 'Annual Filings'), as required under applicable Canadian securities laws..

不列颠哥伦比亚省温哥华市——（新闻文件公司——2024年5月2日）——PreveCeutical Medical Inc.（CSE：PREV）（OTCQB：PRVCF）（FSE：18H）（“公司”或“PreveCeutical”）宣布，根据适用的加拿大证券法的要求，公司已错过2024年4月29日的提交截止日期，无法提交公司截至2023年12月31日的财年经审计的年度财务报表以及随附的管理层讨论和分析，以及相关的首席执行官和首席财务官证书（统称为“年度备案”）。。

In connection with the Company's inability to file the Annual Filings on time, the Company applied for a Management Cease Trade Order ('MCTO') under National Policy 12-203 - Management Cease Trade Orders ('NP 12-203') and the MCTO was issued by the British Columbia Securities Commission effective as of May 2, 2024..

由于公司无法按时提交年度申报，公司根据国家政策12-203-管理层停牌令（“NP 12-203”）申请了管理层停牌令（“MCTO”），并且该MCTO由不列颠哥伦比亚省证券委员会发布，自2024年5月2日起生效。。

The Company was unable to file its Annual Filings within the required time due to a lack of funds, which prevented the Company from engaging its auditors and completing its audit in a timely manner. The Company expects to file the Annual Filings as soon as they are available, but in any event no later than June 28, 2024..

由于缺乏资金，该公司无法在规定的时间内提交年度申报，因此无法聘请审计师并及时完成审计。该公司希望在年度申报可用时尽快提交，但无论如何不迟于2024年6月28日。。

The Company will issue a news release once the Annual Filings have been filed. Until the Company files the Annual Filings, it will comply with the alternative information guidelines set out in NP 12-203. The guidelines, among other things, require the Company to issue bi-weekly default status reports, in the form of news releases, for so long as the Annual Filings have not been filed..

一旦提交年度申请，公司将发布新闻稿。在公司提交年度备案之前，它将遵守NP 12-203中规定的替代信息指南。除其他事项外，该指南要求该公司以新闻稿的形式发布每两周一次的违约状态报告，只要年度备案尚未提交。。

The Company also anticipates completing a private placement for gross proceeds of up to $250,000 (the 'Proposed Private Placement') in the near future, and expects to use the proceeds of the Proposed Private Placement for working capital purposes, including payment of audit related fees. The Company will provide further details on the Proposed Private Placement in a subsequent news release..

该公司还预计在不久的将来完成总收益高达250000美元的私募（“拟议私募”），并预计将拟议私募的收益用于营运资金，包括支付审计相关费用。该公司将在随后的新闻稿中提供有关拟议私募的进一步细节。。

During the MCTO, the general investing public will continue to be able to trade in the Company's common shares (the 'Shares') listed on the Canadian Securities Exchange. However, the Company's CEO, CFO and such other directors, officers and persons as determined by the applicable regulatory authorities will not be able to trade in the Shares, nor will the Company be able to, directly or indirectly, issue securities to or acquire securities from an insider or employee of the Company except in accordance with legally binding obligations to do so existing as of April 29, 2024, being the date of the Company's anticipated continuous disclosure default..

在MCTO期间，普通投资公众将继续能够交易在加拿大证券交易所上市的公司普通股（“股票”）。然而，本公司首席执行官、首席财务官以及适用监管机构确定的其他董事、高级职员和人员将无法交易股份，也无法直接或间接向本公司内部人士或员工发行证券或从其处购买证券，除非根据截至2024年4月29日（即本公司预期的持续披露违约日期）存在的具有法律约束力的义务。。

The Company is not subject to any insolvency proceedings. If the Company provides any information to any of its creditors during the period in which it is in default of filing the Annual Filings, the Company confirms that it will also file material change reports on SEDAR+ containing such information..

公司不受任何破产程序的约束。如果公司在未提交年度备案的期间向其任何债权人提供任何信息，公司确认其也将在SEDAR+上提交包含此类信息的重大变更报告。。

About PreveCeutical

关于PreviCeutical

PreveCeutical is a health sciences company focused on developing innovative options for preventive and curative therapies utilizing organic and nature identical products. The Company aims to be a leader in the preventive health sciences sector.

PreveCeutical是一家健康科学公司，专注于开发利用有机和天然相同产品的预防和治疗疗法的创新选择。该公司旨在成为预防健康科学领域的领导者。

With the completion of three of its research programs, the Company is actively working on the development, clinical trials, and commercialization of its products; and has filed a number of provisional patent applications to protect the intellectual property from its research programs.

随着三个研究项目的完成，该公司正在积极致力于其产品的开发，临床试验和商业化；并提交了一些临时专利申请，以保护其研究计划中的知识产权。

For more information about PreveCeutical, please visit our website www.PreveCeutical.com or follow us on Twitter and Facebook.

有关PreveCeutical的更多信息，请访问我们的网站www。PreveCeutical.com或在推特和脸书上关注我们。

On behalf of the Board of Directors of PreveCeutical

PreveCeutical董事会代表

Stephen Van Deventer, Chairman, Chief Executive Officer and interim Chief Financial Officer

Stephen Van Deventer，董事长、首席执行官和临时首席财务官

For further information, please contact:

欲了解更多信息，请联系：

Stephen Van Deventer: +1 604 306 9669

斯蒂芬·范·德文特（StephenVanDeventer）：+1 604 306 9669

Or Investor Relations ir@preveceutical.com

或投资者关系ir@preveceutical.com

Forward-Looking Statements

前瞻性声明

Cautionary Note Regarding Forward-Looking Statements: This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events.

关于前瞻性声明的注意事项：本新闻稿包括某些可能构成适用加拿大证券法意义上的前瞻性信息的声明和信息。前瞻性陈述与未来事件或未来表现有关，反映了公司管理层对未来事件的期望或信念。

Generally, forward-looking statements and information can be identified using forward-looking terminology such as 'intends' or 'anticipates', or variations of such words and phrases or statements that certain actions, events or results 'may', 'could', 'should', 'would' or 'occur'. This information and these statements, referred to herein as 'forward‐looking statements', are not historical facts, are made as of the date of this news release and include without limitation, statements regarding discussions of future plans, estimates and forecasts and statements as to management's expectations and intentions with respect to, among other things: the Company's Proposed Private Placement; the Company's plans relating to the development, clinical trials and commercialization of its products; management expectations that it will be able to file the Annual Filings within the time period described herein..

一般来说，前瞻性陈述和信息可以使用前瞻性术语来识别，例如“意图”或“预期”，或者这些单词和短语的变体或某些行动、事件或结果“可能”、“可能”、“应该”、“将会”或“发生”的陈述。本信息和这些声明（在本文中称为“前瞻性声明”）并非历史事实，是在本新闻稿发布之日做出的，包括但不限于关于未来计划、估计和预测讨论的声明，以及关于管理层对公司拟议私募的期望和意图的声明；公司有关其产品开发、临床试验和商业化的计划；管理层期望它能够在本文所述的时间段内提交年度备案。。

These forward‐looking statements involve numerous risks and uncertainties and actual results might differ materially from results suggested in any forward-looking statements. These risks and uncertainties include, among other things: the Company being unable to execute its business plans as intended; the Company being unable to file the Annual Filings in the proposed timeframe; the Company being unable to complete the Proposed Private Placement; recent market volatility; and the state of the financial markets for the Company's securities..

这些前瞻性陈述涉及许多风险和不确定性，实际结果可能与任何前瞻性陈述中建议的结果存在重大差异。这些风险和不确定性包括：公司无法按预期执行其业务计划；公司无法在拟定的时间范围内提交年度备案；公司无法完成拟议的私募；近期市场波动；以及公司证券的金融市场状况。。

In making the forward-looking statements in this news release, the Company has applied certain material assumptions, including without limitation, that: the Company will be able to execute its business plans as intended; the Company will be able to file the Annual Filings in the proposed time frame..

在本新闻稿中做出前瞻性声明时，公司已应用了某些重大假设，包括但不限于：公司将能够按预期执行其业务计划；该公司将能够在拟议的时间范围内提交年度备案。。

Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended.

尽管公司管理层试图确定可能导致实际结果与前瞻性声明或前瞻性信息中所含结果存在重大差异的重要因素，但可能还有其他因素导致结果与预期、估计或预期不符。

There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes.

由于实际结果和未来事件可能与此类报表中预期的结果和事件存在重大差异，因此无法保证此类报表将被证明是准确的。因此，读者不应过度依赖前瞻性陈述和前瞻性信息。读者应注意，依赖此类信息可能不适合用于其他目的。

The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor..

本公司不承诺更新通过引用纳入本文的任何前瞻性声明、前瞻性信息或财务展望，除非符合适用的证券法。我们寻求安全港。。

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/207832

要查看此新闻稿的源版本，请访问https://www.newsfilecorp.com/release/207832